TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
PainChek Ltd ( (AU:PCK) ) has provided an announcement.
PainChek Limited announced a change in the director’s interest, with Philip Daffas converting 2,360,718 performance rights into fully paid ordinary shares and allowing 4,804,177 performance rights to lapse. This change reflects a strategic adjustment in the director’s holdings, potentially impacting the company’s stock dynamics and signaling confidence in the company’s future prospects.
More about PainChek Ltd
PainChek Limited operates in the healthcare technology industry, offering innovative pain assessment solutions. The company’s primary product is an AI-powered pain assessment tool designed to improve pain management, particularly for individuals unable to communicate their pain effectively.
Average Trading Volume: 4,932,528
Technical Sentiment Signal: Buy
Current Market Cap: A$102.3M
Find detailed analytics on PCK stock on TipRanks’ Stock Analysis page.